Clinical Trials Logo

Mesothelioma Malignant Advanced clinical trials

View clinical trials related to Mesothelioma Malignant Advanced.

Filter by:
  • None
  • Page 1

NCT ID: NCT05188859 Not yet recruiting - Clinical trials for Mesothelioma, Malignant

First Line Sintilimab Combined With Anlotinib and Platinum Doublet Chemotherapy in Malignant Pleural Mesothelioma

Start date: January 2022
Phase: Phase 2
Study type: Interventional

This study is a single-arm, open-lable, single-center phase II clinical trial for patients with advanced or metastatic pleural mesothelioma. The aim of this study was to observe and evaluate the efficacy and safety of Sintilimab combined with Anlotinib hydrochloride and platinum-containing dual-agent chemotherapy as first-line therapy in malignant pleural mesothelioma.

NCT ID: NCT04181411 Not yet recruiting - Clinical trials for Mesothelioma Malignant Advanced

DREAM3R: DuRvalumab (MEDI4736) With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma

DREAM3R
Start date: March 2020
Phase: Phase 3
Study type: Interventional

The purpose of this study is to investigate the effectiveness of durvalumab in combination with standard chemotherapy for mesothelioma. All participants in the study will receive standard first-line chemotherapy for mesothelioma. Two thirds of the participants in the study will be randomly assigned to also receive a new treatment called durvalumab. Durvalumab is an antibody (a type of human protein) that works by blocking a body substance called Programmed death-ligand 1 (PD-L1). Blocking PD-L1 helps the body's immune system to attack cancer cells. Research has shown that durvalumab can slow tumour growth and shrink tumours in some people with cancer. Previous studies of combining durvalumab and chemotherapy showed that this combination is active in advanced mesothelioma. This international study is being led jointly by the University of Sydney in Australia, and the Pr Eastern Cooperative Oncology Group (PrECOG) in the USA. The study plans to enrol 480 participants from hospitals throughout Australia, New Zealand and the USA.